Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Pharma and EVERSANA Announce Positive Findings from Second GIMOTI® Market Research Study
Results demonstrate continued increased awareness and intent to prescribe GIMOTI SOLANA BEACH, Calif. and CHICAGO , June 15, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA™, a
View HTML
Toggle Summary Evoke Pharma and EVERSANA Announce Support of The International Foundation for Gastrointestinal Disorders’ (IFFGD) August Gastroparesis Awareness Month
Participating and Sponsorship in Upcoming Digestive Health Virtual Walk SOLANA BEACH, Calif. , Aug. 02, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma ® (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA ™ , a leading provider of global
View HTML
Toggle Summary Evoke Pharma and EVERSANA Announce the Appointment of Christopher Quesenberry as Chief Commercial Officer for Gimoti™
Gimoti commercial launch on track for the fourth quarter of 2020 SOLANA BEACH, Calif. and CHICAGO , Aug. 25, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases and EVERSANA™, a leading provider of
View HTML
Toggle Summary Evoke Pharma and EVERSANA Expand Patient Access to GIMOTI® With New Telehealth Solution
Patients With Symptoms of Diabetic Gastroparesis Now Have Direct-to-Patient Treatment Support Powered by UpScriptHealth SOLANA BEACH, Calif. and CHICAGO , Aug. 16, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company primarily focused on treatments for
View HTML
Toggle Summary Evoke Pharma and EVERSANA Extend Commercialization Partnership to Further Support GIMOTI
SOLANA BEACH, Calif. and CHICAGO , Feb. 02, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company primarily focused on treatments for gastrointestinal (GI) diseases, and EVERSANA Life Science Services, LLC , an independent provider of global commercial
View HTML
Toggle Summary Evoke Pharma and EVERSANA Launch Social Media Campaign for Gimoti® Nasal Spray
Evoke is committed to meeting patients online, where they search for answers New campaign leverages Facebook to satisfy significant unmet need for education and community SOLANA BEACH, Calif. and CHICAGO , May 27, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.
View HTML
Toggle Summary Evoke Pharma and EVERSANA Selected to Present Results of Real-World Healthcare Utilization Study Comparing GIMOTI® and Oral Metoclopramide at the Digestive Disease Week Plenary Session
Distinguished event features the year’s best abstracts and invited speakers in their fields SOLANA BEACH, Calif. , Feb. 21, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an
View HTML
Toggle Summary Evoke Pharma Announces $10 Million Registered Direct Offering Priced At-The-Market
SOLANA BEACH, Calif., July 29, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK) ("Evoke Pharma" or "the Company"), today announced that it has entered into definitive agreements with institutional investors for an offering of shares of common stock with gross proceeds of approximately $10
View HTML
Toggle Summary Evoke Pharma Announces $4.5 Million At-The-Market Offering
SOLANA BEACH, Calif., July 20, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK) (the "Company"), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has entered into definitive agreements with institutional investors for an
View HTML
Toggle Summary Evoke Pharma Announces a Fireside Chat with Key Opinion Leaders on the Treatment of Gastroparesis
SOLANA BEACH, Calif. , March 30, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a commercial stage specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that Yale Jen, Senior Biotech Analyst at Laidlaw & Company will
View HTML